This, along with the data presented here, makes this molecule an attractive clinical candidate for ALK+ ALCL and justifies the design of novel clinical trials employing OTX015 in association with inhibitors of ITK or SHH/GLI1 signaling for the treatment of relapsed or refractory ALK+ ALCL. This evidence concerns the gene ALK and anaplastic large cell lymphoma.